Costs per individual for inpatient care, outpatient care, and reimbursed drugs during the 6-month follow-up
| All patients | Patients with EQ-5D utility scores at baseline and at 6-month follow-up | |||
| Intervention (n=164) | Control (n=181) | Intervention (n=116) | Control (n=124) | |
| Total | 4751 (1852–14 145) 10 615±13 795 | 4146 (1589–14 110) 10 344±14 728 | 4838 (2045–13 812) 10 776±13 995 | 3514 (1437–12 098) 9290±12 885 |
| Inpatient care | 0 (0–9907) 7756±13 037 | 0 (0–9324) 7328±13 849 | 1166 (0–10 490) 7891±13 291 | 0 (0–9130) 6398±11 958 |
| Outpatient care | 1728 (806–2863) 2041±1660 | 1786 (1011–2803) 2184±1912 | 1768 (806–3000) 1995±1579 | 1760 (987–2650) 2080±1790 |
| Reimbursed drugs | 508 (194–1006) 819±1038 | 476 (187–932) 832±1452 | 538 (223–1106) 891±1147 | 435 (159–838) 812±1610 |
Values as presented in Euro (€) as median (IQR) and mean±SD.
EQ-5D, EuroQol-5 dimensions.